摘要
目的比较疏血通和尿激酶治疗前臂动静脉内瘘(AVF)血栓性阻塞的效果及血液流变学变化。方法用疏血通注射液和尿激酶治疗血液透析患者AVF血栓性阻塞各20例,均7d为1个疗程。对比AVF复通效果及用药前后血液流变学改变。结果疏血通与尿激酶对AVF部分阻塞的治疗均完全成功,但对完全阻塞疗效不佳。治疗后,疏血通与尿激酶组纤维蛋白原均显著下降〔(3.46±1.32)g/Lvs(4.56±1.05)g/L,P<0.01;(3.35±1.18)g/Lvs(4.68±1.49)g/L,P<0.01〕;血浆黏度值显著下降(P<0.01);红细胞聚集指数明显改善(P<0.05)。疏血通组未发生药物不良反应,尿激酶组8例动脉穿刺点出血、瘀血。结论疏血通能替代出血风险较大的尿激酶治疗AVF血栓形成致血管部分阻塞,可作为维护血液透析血管通路的常规治疗用药,具有良好的安全性。
Objective To compare thrombolytic effect of Shuxuetong and Urokinase on forearm arterio-venous fistulas（AVF） emphraxis. Methods Forty patients with AVF emphraxis were divided into Shuxuetong group and Urokinase group（ n = 20 each） , respectively accepted Shuxuetong injection and Urokinase for a week. Their effect on recovering AVF emphraxis was compared, and the changes of hemorheology were analyzed. Results The effects of Shuxuetong and Urokinase were both good on thrombolysis in AVF partial emphraxis, but unsatisfactory in AVF complete emphraxis. After treatment ,fibrinogen were significantly descended in both Shuxuetong group and Urokinase group[（3.46 ± 1.32 ）g/ L vs （4. 56 ± 1.05） g/L,P 〈0. 01 ; （3.35 ± 1.18） g/L vs（ 4.68 ± 1.49） g/L,P 〈0. 01 ] ;as well as plasma viscosity and erythrocyte aggregation index were also descended（P 〈0. 01 ,P 〈0. 05）. There were no drug-adverse react in Shuxuetong group, while bleeding and ecchymosis of arterial puncting position occurred in 8 cases of Urokinase group. Conduslons Shuxuetong can substitute Urokinase to solve AVF partial emphraxis caused by thrombosis in vascular access ,and it could be presented as a conventional therapeutic drug for protecting vascular access with less adverse effects.
出处
《中国厂矿医学》
2009年第3期266-267,共2页
Chinese Medicine of Factory and Mine
基金
广西中医学院自然科学基金资助项目(P2005066)
